Aligos Therapeutics Files 2024 10-K, Details Key Agreements
Ticker: ALGS · Form: 10-K · Filed: Mar 10, 2025 · CIK: 1799448
| Field | Detail |
|---|---|
| Company | Aligos Therapeutics, Inc. (ALGS) |
| Form Type | 10-K |
| Filed Date | Mar 10, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, biotech, licensing-agreement, equity-offering
TL;DR
Aligos 10-K dropped: Key deals with Luxna & Amoytop, plus a Feb 2025 warrant offering. Check financials.
AI Summary
Aligos Therapeutics, Inc. filed its 2024 10-K on March 10, 2025, reporting on its fiscal year ending December 31, 2024. The company is involved in the development of biological products, specifically focusing on treatments related to liver diseases and viral infections. Key agreements mentioned include the Luxna License Agreement with Luxna Biotech Co., Ltd. and the Amoytop License and Research Collaboration with Amoytop. The company also completed a Private Investment in Public Equity Offering and issued Pre-Funded Warrants and Common Warrants on February 13, 2025.
Why It Matters
This filing provides investors with a comprehensive overview of Aligos Therapeutics' financial health, strategic partnerships, and ongoing research and development efforts for the past fiscal year.
Risk Assessment
Risk Level: medium — Biotech companies like Aligos Therapeutics are inherently risky due to the long and uncertain development cycles for new drugs and therapies.
Key Numbers
- 2024 — Fiscal Year End (The period covered by the 10-K filing.)
- 2025-03-10 — Filing Date (The date the 10-K was officially submitted to the SEC.)
- 2023-12-31 — Prior Year End (Provides a comparative point for financial performance.)
Key Players & Entities
- Aligos Therapeutics, Inc. (company) — Filer of the 10-K
- Luxna Biotech Co., Ltd. (company) — Party to the Luxna License Agreement
- Amoytop (company) — Party to the Amoytop License and Research Collaboration
- February 13, 2025 (date) — Date of Private Investment in Public Equity Offering and warrant issuance
- December 31, 2024 (date) — Fiscal year end for the reported period
FAQ
What is the primary business of Aligos Therapeutics, Inc.?
Aligos Therapeutics, Inc. is focused on the development of biological products, specifically in the area of liver diseases and viral infections, as indicated by its SIC code and the context of its filings.
What were the significant events or agreements for Aligos Therapeutics around the end of 2024 or early 2025?
The filing mentions a Private Investment in Public Equity Offering and the issuance of Pre-Funded Warrants and Common Warrants on February 13, 2025.
Who are the key partners mentioned in Aligos Therapeutics' collaborations?
Key partners mentioned include Luxna Biotech Co., Ltd. through the Luxna License Agreement and Amoytop through the Amoytop License and Research Collaboration.
When did Aligos Therapeutics file its 10-K for the fiscal year ending December 31, 2024?
Aligos Therapeutics filed its 10-K for the fiscal year ending December 31, 2024, on March 10, 2025.
What is the company's primary industry classification?
The company's Standard Industrial Classification (SIC) is BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836].
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 10, 2025 regarding Aligos Therapeutics, Inc. (ALGS).